Exhibit 1268 ยท Statute
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023, Pub. L. 117-180, Division F (FDA User Fee Reauthorization Act of 2022), sec. 1005
Sections 735 and 736 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379g; 379h) shall cease to be effective October 1, 2027.
Division F of the Act reauthorizes the prescription drug, device, generic drug and biosimilar user fee programs. Section 1005(a) ends the prescription drug fee authority on 1 October 2027, and section 1005(c) repeals, effective 1 October 2022, the previous sunset provision in section 104 of the FDA Reauthorization Act of 2017.
- Source
- U.S. Congress
- Date
- 30 September 2022
- Quoted from
- Div. F, sec. 1005(a)
- Grade
- Primary record
- Document
- https://www.govinfo.gov/content/pkg/PLAW-117publ180/html/PLAW-117publ180.htm
- Accessed
- 2026-11-10
- Cited by
- Findings citing this exhibit
- Note
- Approved 30 September 2022 (H.R. 6833).